In October 2018, the SUPPORT for Patients and Communities Act was signed into law. This bipartisan legislation offered a comprehensive response to the prescription opioid abuse epidemic — its enactment marked a significant step towards advancing meaningful solutions to address this public health crisis.
With a new year in full swing, HDA President and CEO John M. Gray looked ahead to the organization’s 2019 priorities (along with other industry association executives) as part of the Chain Drug Review “Pharmacy Outlook” feature.
A new report by Avalere Health, "Trends in Opioid Use: History, Background, and Origins of the Epidemic," comes at a critical point in the broader discussion about opioid abuse and misuse, and provides important context around the clinical, regulatory and policy milestones that contributed to the public health epidemic and impacted the national response to the crisis.
Disposing of unused prescription opioids safely and as soon as they are no longer needed can help prevent these medicines from falling into the wrong hands. Data show that opioid misuse often starts in the home, with more than 40 percent of those who misused prescription pain relievers obtaining the medication from a friend or relative for free.
Efforts to mitigate the prescription drug abuse epidemic and activities surrounding DSCSA implementation once again top the list of priorities HDA will be addressing in the year ahead, according to HDA President and CEO John M. Gray. Mr. Gray provided his perspective, along with other healthcare supply chain leaders, as part of Chain Drug Review’s annual “Pharmacy Outlook” feature, published in the January 1 issue.
The Washington Post and 60 Minutes have done a major disservice to the battle against opioid abuse with their biased and one-sided reporting, specifically related to the Ensuring Patient Access and Effective Drug Enforcement Act. Their reporting was based primarily on the word of a former Drug Enforcement Administration (DEA) official, Joe Rannazzisi, who is now a consultant to trial lawyers suing the industry, as noted in both outlets.
Two years ago, Congress approved bipartisan legislation to address the rapidly growing opioid epidemic. Yet today, that legislation — S.483: Ensuring Patient Access and Effective Drug Enforcement Act — is the subject of two upcoming media reports which mischaracterize the intent and outcome of the legislation.
In an op-ed published in the Capitol Hill newspaper, The Hill, HDA President and CEO John M. Gray noted that a commitment and robust effort from all supply chain stakeholders are necessary to help mitigate the nation’s opioid abuse epidemic. Mr. Gray also recognized the critical role of primary pharmaceutical distributors, who stand ready to be part of the solution.
Ahead of the HDA Business and Leadership Conference, President and CEO John M. Gray was interviewed by Chain Drug Review as part of the publication’s "Annual Report of Drug Wholesalers."
HDA President and CEO John M. Gray has outlined the organization’s priorities for the upcoming year in his annual “Pharmacy Outlook” column, published in the January 2 issue of Chain Drug Review.